Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
DGX

DGX - Quest Diagnostics Inc Stock Price, Fair Value and News

146.00USD-0.84 (-0.57%)Market Closed

Market Summary

DGX
USD146.00-0.84
Market Closed
-0.57%

DGX Stock Price

View Fullscreen

DGX RSI Chart

DGX Valuation

Market Cap

16.2B

Price/Earnings (Trailing)

19.17

Price/Sales (Trailing)

1.75

EV/EBITDA

13.89

Price/Free Cashflow

17.13

DGX Price/Sales (Trailing)

DGX Profitability

Operating Margin

32.87%

EBT Margin

12.05%

Return on Equity

13.15%

Return on Assets

6.06%

Free Cashflow Yield

5.84%

DGX Fundamentals

DGX Revenue

Revenue (TTM)

9.3B

Rev. Growth (Yr)

1.5%

Rev. Growth (Qtr)

3.41%

DGX Earnings

Earnings (TTM)

846.0M

Earnings Growth (Yr)

-3.96%

Earnings Growth (Qtr)

1.04%

Breaking Down DGX Revenue

Last 7 days

1.3%

Last 30 days

6.3%

Last 90 days

13.7%

Trailing 12 Months

1.7%

How does DGX drawdown profile look like?

DGX Financial Health

Current Ratio

0.97

Debt/Equity

0.59

Debt/Cashflow

0.35

DGX Investor Care

Dividend Yield

1.97%

Dividend/Share (TTM)

2.88

Buy Backs (1Y)

0.81%

Diluted EPS (TTM)

7.43

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.3B000
20239.6B9.5B9.3B9.3B
202210.7B10.6B10.3B9.9B
202110.3B11.1B11.0B10.8B
20207.7B7.5B8.4B9.4B
20197.5B7.6B7.6B7.7B
20187.5B7.5B7.6B7.5B
20177.5B7.4B7.4B7.4B
20167.5B7.5B7.5B7.5B
20157.5B7.6B7.5B7.5B
20147.2B7.3B7.4B7.4B
20137.3B7.2B7.2B7.1B
20127.5B7.5B7.5B7.4B
20117.4B7.4B7.4B7.4B
20107.5B7.4B7.4B7.4B
20097.3B7.3B7.4B7.5B
200806.9B7.1B7.2B
20070006.7B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Quest Diagnostics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 16, 2024
samad sam
sold (taxes)
-557,762
142
-3,910
executive vice president & cfo
May 16, 2024
lassiter wright iii
acquired
-
-
2,964
-
May 16, 2024
ring timothy m
acquired
-
-
1,482
-
May 16, 2024
morrison denise m
acquired
-
-
1,482
-
May 16, 2024
pfeiffer gary m
acquired
-
-
1,482
-
May 16, 2024
carter robert b
acquired
-
-
1,482
-
May 16, 2024
gregg vicky b
acquired
-
-
1,482
-
May 16, 2024
main timothy l
acquired
-
-
1,482
-

1–10 of 50

Which funds bought or sold DGX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
PARSONS CAPITAL MANAGEMENT INC/RI
reduced
-0.45
31,420
1,358,260
0.09%
Jul 19, 2024
WASHINGTON CAPITAL MANAGEMENT, INC
unchanged
-
16,983
616,644
0.52%
Jul 19, 2024
HOYLECOHEN, LLC
reduced
-6.71
-158,193
3,733,460
0.28%
Jul 19, 2024
Greenspring Advisors, LLC
unchanged
-
7,231
262,536
0.06%
Jul 19, 2024
First Horizon Advisors, Inc.
added
4.85
1,730
23,703
-%
Jul 19, 2024
KFG WEALTH MANAGEMENT, LLC
reduced
-1.76
2,329
229,548
0.09%
Jul 19, 2024
KAVAR CAPITAL PARTNERS GROUP, LLC
reduced
-1.42
25,566
1,894,830
0.34%
Jul 19, 2024
Riverwater Partners LLC
reduced
-0.55
30,921
1,393,340
1.03%
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
-3.00
411
-%
Jul 19, 2024
Oakworth Capital, Inc.
unchanged
-
312
11,361
-%

1–10 of 50

Are Funds Buying or Selling DGX?

Are funds buying DGX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DGX
No. of Funds

Unveiling Quest Diagnostics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
12.07%
13,575,974
SC 13G/A
Jan 25, 2024
state street corp
4.76%
5,352,341
SC 13G/A
Jan 24, 2024
blackrock inc.
9.4%
10,578,025
SC 13G/A
Feb 09, 2023
vanguard group inc
12.27%
13,973,339
SC 13G/A
Feb 07, 2023
state street corp
5.16%
5,879,980
SC 13G/A
Jan 23, 2023
blackrock inc.
10.9%
12,391,327
SC 13G/A
Apr 08, 2022
blackrock inc.
10.7%
12,807,624
SC 13G/A
Feb 10, 2022
state street corp
5.11%
6,268,789
SC 13G
Feb 07, 2022
blackrock inc.
9.5%
11,636,382
SC 13G/A
Feb 10, 2021
vanguard group inc
10.64%
14,337,685
SC 13G/A

Recent SEC filings of Quest Diagnostics Inc

View All Filings
Date Filed Form Type Document
Jul 18, 2024
4
Insider Trading
Jul 03, 2024
8-K
Current Report
Jul 02, 2024
4
Insider Trading
Jun 21, 2024
11-K
Employee Benefit Details
May 21, 2024
8-K
Current Report
May 21, 2024
8-K
Current Report
May 20, 2024
4
Insider Trading
May 20, 2024
3
Insider Trading
May 20, 2024
4
Insider Trading
May 20, 2024
4
Insider Trading

Peers (Alternatives to Quest Diagnostics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
23.7B
-5.41% 12.43%
40.98
7.6
-8.94% -35.91%
38.7B
3.7B
-7.03% -13.75%
44.62
10.38
8.57% 23.94%
38.5B
6.6B
-2.30% 5.82%
30.96
5.83
-6.38% -8.07%
16.2B
9.3B
6.34% 1.67%
19.17
1.75
-3.29% 6.68%
13.0B
2.0B
4.50% 70.57%
41.75
6.65
25.57% 21.62%
13.0B
1.2B
-1.84% 123.25%
-35.62
10.77
39.26% 33.08%
11.2B
4.1B
4.05% 7.02%
25.3
2.73
0.49% -10.45%
MID-CAP
8.6B
2.5B
11.64% -50.70%
-35.95
3.41
15.21% 53.51%
3.8B
603.7M
2.74% -17.56%
-8.17
6.23
25.21% 30.68%
3.5B
929.2M
-2.97% -26.96%
2.3K
3.81
28.93% 111.61%
SMALL-CAP
942.7M
275.1M
28.64% 80.46%
-5.15
3.43
-13.93% -126.97%
94.1M
31.1M
16.81% -87.36%
-1.22
3.02
0.95% 19.75%
18.8M
9.0M
-7.93% -45.09%
-1.28
2.09
4.46% 45.80%
393.9K
5.5M
-13.04% -71.63%
-0.03
0.07
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Quest Diagnostics Inc News

Latest updates
MarketBeat2 hours ago
American Banking and Market News15 hours ago
Yahoo Finance17 Jul 202401:50 pm

Quest Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue3.4%2,3662,2882,2952,3382,3312,3332,4862,4532,6112,7442,7742,5502,7203,0022,7861,8271,8221,9261,9561,9531,891
Cost Of Revenue2.8%1,5951,5521,5411,5461,5601,5751,6181,6111,6461,7181,6701,5651,6261,7331,5801,2211,2701,2641,2641,2651,244
Costs and Expenses2.2%2,0662,0211,9531,9902,0262,1982,0942,0652,0982,2082,1222,0172,0602,2072,0681,5441,6471,5631,6431,6461,643
  S&GA Expenses8.1%440407380416439563464422425464427429407447396360347349362362384
EBITDA Margin-1.1%0.15*0.15*0.14*0.14*0.14*0.16*0.19*0.21*0.25*0.26*0.28*0.29*0.25*0.22*0.20*0.15*0.15*0.16*---
Interest Expenses-7.5%-43.00-40.00-40.00-37.00-35.00-32.00-33.00-36.00-37.00-37.00-38.00-38.00-38.00-39.00-42.00-41.00-41.00-42.00-44.00-45.00-44.00
Income Taxes65.0%66.0040.0068.0075.0065.00-4.0081.0077.0011011415317715319117766.0026.0072.0062.0063.0050.00
Earnings Before Taxes12.2%266237299317277109351323452502654817626758753255118328270265213
EBT Margin-1.3%0.12*0.12*0.11*0.11*0.11*0.12*0.16*0.18*0.23*0.24*0.26*0.27*0.23*0.20*0.17*0.13*0.13*0.14*---
Net Income1.0%19419222523520210125623435539050563146957956818599.00253215226164
Net Income Margin-1.3%0.09*0.09*0.08*0.08*0.08*0.10*0.12*0.14*0.18*0.18*0.20*0.20*0.17*0.15*0.13*0.10*0.10*0.11*---
Free Cashflow-89.0%50.00455102340-33.00187384326417337472376645379771273164176---
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.5%13,95414,02213,48213,42512,79412,83713,22313,31213,44213,61113,57212,86113,93114,02614,14312,99012,04912,84312,01911,76011,937
  Current Assets-6.1%2,2282,3721,8151,7331,8141,8982,3342,4262,4752,7412,8542,1462,9993,0583,3482,3801,5602,4901,7791,5661,778
    Cash Equivalents-30.9%4746861431261753157007907128729875601,2301,1581,6059883421,192434273464
  Inventory-4.7%18119018418419019218318719720820519922322320515412612311210598.00
  Net PPE-0.3%1,8101,8161,8301,8141,7951,7661,7071,6641,6681,7071,6341,6221,6241,6271,5441,5051,4611,4531,3511,3071,277
  Goodwill1.3%7,8307,7337,7322677,2417,2207,1907,1957,1977,0957,0577,0456,8706,8736,8806,78993.00----
  Current Liabilities26.6%2,2981,8151,6181,8751,3551,5511,6021,5771,7001,7531,7591,5511,7071,7762,3891,8431,1291,9902,0111,9042,282
  Long Term Debt-13.7%3,8044,4103,9463,7773,9753,9783,9803,9833,9854,0104,0064,0084,0104,0134,0184,0204,0333,9663,1883,1693,131
    LT Debt, Current199.0%9063033045182.002.002.002.002.002.001.002.002.002.005555553.00804---
Shareholder's Equity2.0%6,4326,3076,4256,2876,0885,9306,2726,4506,4156,4836,4325,9406,7906,8096,4465,8815,7035,6875,6545,5095,341
  Retained Earnings1.2%8,9358,8258,7118,5668,4128,2908,2638,0837,9267,6497,33310,2469,6909,3038,8008,3078,1978,1747,9927,8497,694
  Additional Paid-In Capital-1.2%2,2922,3202,3022,2842,2662,2952,2722,2502,2262,2601,9362,5552,8242,8412,8012,7642,7382,7222,7052,6862,671
Shares Outstanding-111-112112112-116117119-127125133-134134134-135135134
Minority Interest5.7%37.0035.0038.0038.0038.0037.0037.0039.0038.0039.0040.0041.0045.0050.0046.0050.0046.0046.0049.0050.0051.00
Float----15,700---15,400---16,100---15,200---13,700-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-70.8%15452720744494.00334502402480481561460731541862355247348299321275
  Share Based Compensation15.8%22.0019.0018.0016.0024.0022.0018.0019.0018.0019.0021.0021.0018.0034.0032.0017.0014.0012.0012.0015.0017.00
Cashflow From Investing-86.8%-213-114-107-682-158-174-118-82.00-169-227-96.00437-93.00-168-193-205-206-100-109-92.00-110
Cashflow From Financing-217.7%-153130-83.00189-76.00-545-474-242-471-369-38.00-1,567-566-820-52.00496-891510-29.00-420164
  Dividend Payments-1.2%79.0080.0080.0080.0074.0075.0078.0078.0074.0077.0076.0081.0075.0075.0076.0075.0071.0071.0072.0071.0072.00
  Buy Backs-100.0%-275---461374200373289-1,500410250--75.0020050.0050.0053.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

DGX Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net revenues$ 2,366$ 2,331
Operating costs and expenses and other operating income:  
Cost of services1,5951,560
Selling, general and administrative440439
Amortization of intangible assets2926
Other operating expense, net21
Total operating costs and expenses, net2,0662,026
Operating income300305
Other income (expense):  
Interest expense, net(43)(35)
Other income, net97
Total non-operating expense, net(34)(28)
Income before income taxes and equity in earnings of equity method investees266277
Income tax expense(66)(65)
Equity in earnings of equity method investees, net of taxes85
Net income208217
Less: Net income attributable to noncontrolling interests1415
Net income attributable to Quest Diagnostics$ 194$ 202
Earnings per share attributable to Quest Diagnostics’ common stockholders:  
Basic (in dollars per share)$ 1.74$ 1.80
Diluted (in dollars per share)$ 1.72$ 1.78
Weighted average common shares outstanding:  
Basic (in Shares)111112
Diluted (in Shares)112113

DGX Balance Sheet

2024-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Assets  
Cash and cash equivalents$ 474$ 686
Accounts receivable, net of allowance for credit losses of $28 and $27 as of March 31, 2024 and December 31, 2023, respectively1,3221,210
Inventories181190
Prepaid expenses and other current assets251286
Total current assets2,2282,372
Property, plant and equipment, net1,8101,816
Operating lease right-of-use assets579602
Goodwill7,8307,733
Intangible assets, net1,1921,166
Investments in equity method investees133135
Other assets182198
Total assets13,95414,022
Liabilities and Stockholders' Equity  
Accounts payable and accrued expenses1,2391,359
Current portion of long-term debt906303
Current portion of long-term operating lease liabilities153153
Total current liabilities2,2981,815
Long-term debt3,8044,410
Long-term operating lease liabilities489503
Other liabilities817876
Commitments and contingencies
Redeemable noncontrolling interest7776
Quest Diagnostics stockholders’ equity:  
Common stock, par value $0.01 per share; 600 shares authorized as of both March 31, 2024 and December 31, 2023; 162 shares issued as of both March 31, 2024 and December 31, 202322
Additional paid-in capital2,2922,320
Retained earnings8,9358,825
Accumulated other comprehensive loss(16)(14)
Treasury stock, at cost; 51 shares as of both March 31, 2024 and December 31, 2023(4,781)(4,826)
Total Quest Diagnostics stockholders' equity6,4326,307
Noncontrolling interests3735
Total stockholders' equity6,4696,342
Total liabilities and stockholders' equity$ 13,954$ 14,022
DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
 CEO
 WEBSITEquestdiagnostics.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES40000

Quest Diagnostics Inc Frequently Asked Questions


What is the ticker symbol for Quest Diagnostics Inc? What does DGX stand for in stocks?

DGX is the stock ticker symbol of Quest Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Quest Diagnostics Inc (DGX)?

As of Fri Jul 19 2024, market cap of Quest Diagnostics Inc is 16.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers.

What is the fair value of DGX stock?

You can check DGX's fair value in chart for subscribers. The fair value of Quest Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Quest Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Quest Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether DGX is over valued or under valued. Whether Quest Diagnostics Inc is cheap or expensive depends on the assumptions which impact Quest Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DGX.

What is Quest Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, DGX's PE ratio (Price to Earnings) is 19.17 and Price to Sales (PS) ratio is 1.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DGX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Quest Diagnostics Inc's stock?

In the past 10 years, Quest Diagnostics Inc has provided 0.109 (multiply by 100 for percentage) rate of return.